These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18202013)
21. Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy. Sorace AG; Saini R; Mahoney M; Hoyt K J Ultrasound Med; 2012 Oct; 31(10):1543-50. PubMed ID: 23011617 [TBL] [Abstract][Full Text] [Related]
22. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments. Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323 [TBL] [Abstract][Full Text] [Related]
23. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Korpanty G; Carbon JG; Grayburn PA; Fleming JB; Brekken RA Clin Cancer Res; 2007 Jan; 13(1):323-30. PubMed ID: 17200371 [TBL] [Abstract][Full Text] [Related]
24. Rational design of a protein that binds integrin αvβ3 outside the ligand binding site. Turaga RC; Yin L; Yang JJ; Lee H; Ivanov I; Yan C; Yang H; Grossniklaus HE; Wang S; Ma C; Sun L; Liu ZR Nat Commun; 2016 May; 7():11675. PubMed ID: 27241473 [TBL] [Abstract][Full Text] [Related]
26. Targeted contrast-enhanced ultrasound imaging of angiogenesis in an orthotopic mouse tumor model of renal carcinoma. Wei S; Fu N; Sun Y; Yang Z; Lei L; Huang P; Yang B Ultrasound Med Biol; 2014 Jun; 40(6):1250-9. PubMed ID: 24613557 [TBL] [Abstract][Full Text] [Related]
27. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Winkler F; Kozin SV; Tong RT; Chae SS; Booth MF; Garkavtsev I; Xu L; Hicklin DJ; Fukumura D; di Tomaso E; Munn LL; Jain RK Cancer Cell; 2004 Dec; 6(6):553-63. PubMed ID: 15607960 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment. Rix A; Lederle W; Siepmann M; Fokong S; Behrendt FF; Bzyl J; Grouls C; Kiessling F; Palmowski M Eur J Radiol; 2012 Oct; 81(10):2710-6. PubMed ID: 22093958 [TBL] [Abstract][Full Text] [Related]
29. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074 [TBL] [Abstract][Full Text] [Related]
30. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer. Wang H; Lutz AM; Hristov D; Tian L; Willmann JK Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690 [TBL] [Abstract][Full Text] [Related]
31. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339 [TBL] [Abstract][Full Text] [Related]
32. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy? Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA J Nucl Med; 2014 Nov; 55(11):1878-84. PubMed ID: 25278514 [TBL] [Abstract][Full Text] [Related]
33. Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts. Jing Y; Xiu-Juan Z; Hong-Jiao C; Zhi-Kui C; Qing-Fu Q; En-Sheng X; Li-Wu L J Cancer Res Clin Oncol; 2019 May; 145(5):1191-1200. PubMed ID: 30805775 [TBL] [Abstract][Full Text] [Related]
34. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206 [TBL] [Abstract][Full Text] [Related]
35. Computational modeling of synergistic interaction between αVβ3 integrin and VEGFR2 in endothelial cells: Implications for the mechanism of action of angiogenesis-modulating integrin-binding peptides. Bazzazi H; Zhang Y; Jafarnejad M; Popel AS J Theor Biol; 2018 Oct; 455():212-221. PubMed ID: 30036530 [TBL] [Abstract][Full Text] [Related]
37. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. Lee DJ; Lyshchik A; Huamani J; Hallahan DE; Fleischer AC J Ultrasound Med; 2008 Jun; 27(6):855-66. PubMed ID: 18499845 [TBL] [Abstract][Full Text] [Related]
38. The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55). Bzyl J; Palmowski M; Rix A; Arns S; Hyvelin JM; Pochon S; Ehling J; Schrading S; Kiessling F; Lederle W Eur Radiol; 2013 Feb; 23(2):468-75. PubMed ID: 22878592 [TBL] [Abstract][Full Text] [Related]
39. A Lipopeptide-Based αvβ₃ Integrin-Targeted Ultrasound Contrast Agent for Molecular Imaging of Tumor Angiogenesis. Yan F; Xu X; Chen Y; Deng Z; Liu H; Xu J; Zhou J; Tan G; Wu J; Zheng H Ultrasound Med Biol; 2015 Oct; 41(10):2765-73. PubMed ID: 26166460 [TBL] [Abstract][Full Text] [Related]
40. Identification of a Common Pharmacophore for Binding to MMP2 and RGD Integrin: Towards a Multitarget Approach to Inhibit Cancer Angiogenesis and Metastasis. Baldini L; Lenci E; Bianchini F; Trabocchi A Molecules; 2022 Feb; 27(4):. PubMed ID: 35209039 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]